Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

lead Pb 212 pentixather

A radioconjugate composed of pentixather, a chemokine receptor C-X-C chemokine receptor type 4 (CXCR4)-targeting ligand, conjugated to the alpha-emitting radioisotope lead Pb 212, with potential antineoplastic activity. Upon administration, lead Pb 212 pentixather targets and binds to CXCR4-expressing cancer cells. This allows for the specific delivery of a cytotoxic dose of alpha radiation to CXCR4-expressing cancer cells. CXCR4, a marker of poorly differentiated cells, is overexpressed on various cancer cells, and plays a key role in tumor growth, progression, invasiveness and metastasis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:212-lead pentixather
212Pb-pentixather
lead 212-labeled pentixather
lead Pb 212-pentixather
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search